These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer. Houdu B; Lasnon C; Licaj I; Thomas G; Do P; Guizard AV; Desmonts C; Aide N Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):421-428. PubMed ID: 30218317 [TBL] [Abstract][Full Text] [Related]
23. Variation in background intensity affects PET-based gross tumor volume delineation in non-small-cell lung cancer: the need for individualized information. Chen GH; Yao ZF; Fan XW; Zhang YJ; Gao HQ; Qian W; Wu KL; Jiang GL Radiother Oncol; 2013 Oct; 109(1):71-6. PubMed ID: 24060171 [TBL] [Abstract][Full Text] [Related]
24. Repeatability of metabolically active tumor volume measurements with FDG PET/CT in advanced gastrointestinal malignancies: a multicenter study. Frings V; van Velden FH; Velasquez LM; Hayes W; van de Ven PM; Hoekstra OS; Boellaard R Radiology; 2014 Nov; 273(2):539-48. PubMed ID: 24865311 [TBL] [Abstract][Full Text] [Related]
25. Performance Evaluation of a Semi-automated Method for [ de Boer SA; Spoor DS; Slart RHJA; Mulder DJ; Reijrink M; Borra RJH; Kramer GM; Hoekstra OS; Boellaard R; Greuter MJ Mol Imaging Biol; 2019 Feb; 21(1):159-167. PubMed ID: 29789994 [TBL] [Abstract][Full Text] [Related]
26. Delineation of lung cancer with FDG PET/CT during radiation therapy. Ganem J; Thureau S; Gardin I; Modzelewski R; Hapdey S; Vera P Radiat Oncol; 2018 Nov; 13(1):219. PubMed ID: 30419929 [TBL] [Abstract][Full Text] [Related]
28. FDG-PET-based differential uptake volume histograms: a possible approach towards definition of biological target volumes. Devic S; Mohammed H; Tomic N; Aldelaijan S; De Blois F; Seuntjens J; Lehnert S; Faria S Br J Radiol; 2016 Jun; 89(1062):20150388. PubMed ID: 27007269 [TBL] [Abstract][Full Text] [Related]
29. Metabolically active tumour volume segmentation from dynamic [(18)F]FLT PET studies in non-small cell lung cancer. Hoyng LL; Frings V; Hoekstra OS; Kenny LM; Aboagye EO; Boellaard R EJNMMI Res; 2015; 5():26. PubMed ID: 25932353 [TBL] [Abstract][Full Text] [Related]
30. Impact of the EARL harmonization program on automatic delineation of metabolic active tumour volumes (MATVs). Lasnon C; Enilorac B; Popotte H; Aide N EJNMMI Res; 2017 Dec; 7(1):30. PubMed ID: 28361349 [TBL] [Abstract][Full Text] [Related]
31. Tumour delineation in oesophageal cancer - A prospective study of delineation in PET and CT with and without endoscopically placed clip markers. Thomas L; Lapa C; Bundschuh RA; Polat B; Sonke JJ; Guckenberger M Radiother Oncol; 2015 Aug; 116(2):269-75. PubMed ID: 26364886 [TBL] [Abstract][Full Text] [Related]
32. Optimization of PET reconstruction algorithm, SUV thresholding algorithm and PET acquisition time in clinical 11C-acetate PET/CT. Strandberg S; Hashemi A; Axelsson J; Riklund K PLoS One; 2018; 13(12):e0209169. PubMed ID: 30543705 [TBL] [Abstract][Full Text] [Related]
33. Sensitivity of Cysouw MCF; Kramer GM; Heijtel D; Schuit RC; Morris MJ; van den Eertwegh AJM; Voortman J; Hoekstra OS; Oprea-Lager DE; Boellaard R EJNMMI Res; 2019 Jul; 9(1):70. PubMed ID: 31363939 [TBL] [Abstract][Full Text] [Related]
34. The influence of different signal-to-background ratios on spatial resolution and F18-FDG-PET quantification using point spread function and time-of-flight reconstruction. Rogasch JM; Hofheinz F; Lougovski A; Furth C; Ruf J; Großer OS; Mohnike K; Hass P; Walke M; Amthauer H; Steffen IG EJNMMI Phys; 2014 Dec; 1(1):12. PubMed ID: 26501454 [TBL] [Abstract][Full Text] [Related]
35. Tumor Delineation and Quantitative Assessment of Glucose Metabolic Rate within Histologic Subtypes of Non-Small Cell Lung Cancer by Using Dynamic Meijer TWH; de Geus-Oei LF; Visser EP; Oyen WJG; Looijen-Salamon MG; Visvikis D; Verhagen AFTM; Bussink J; Vriens D Radiology; 2017 May; 283(2):547-559. PubMed ID: 27846378 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of threshold and gradient based (18)F-fluoro-deoxy-2-glucose hybrid positron emission tomographic image segmentation methods for liver tumor delineation. Altunbas C; Howells C; Proper M; Reddy K; Gan G; DeWitt P; Kavanagh B; Schefter T; Miften M Pract Radiat Oncol; 2014; 4(4):217-25. PubMed ID: 25012829 [TBL] [Abstract][Full Text] [Related]
37. 18F-FDG PET definition of gross tumor volume for radiotherapy of lung cancer: is the tumor uptake value-based approach appropriate for lymph node delineation? Rodríguez N; Sanz X; Trampal C; Foro P; Reig A; Lacruz M; Membrive I; Lozano J; Quera J; Algara M Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):659-66. PubMed ID: 20133071 [TBL] [Abstract][Full Text] [Related]
38. EARL compliance and imaging optimisation on the Biograph Vision Quadra PET/CT using phantom and clinical data. van Sluis J; van Snick JH; Brouwers AH; Noordzij W; Dierckx RAJO; Borra RJH; Slart RHJA; Lammertsma AA; Glaudemans AWJM; Boellaard R; Tsoumpas C Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4652-4660. PubMed ID: 35876867 [TBL] [Abstract][Full Text] [Related]
39. Repeatability of Quantitative 18F-Fluoromethylcholine PET/CT Studies in Prostate Cancer. Oprea-Lager DE; Kramer G; van de Ven PM; van den Eertwegh AJ; van Moorselaar RJ; Schober P; Hoekstra OS; Lammertsma AA; Boellaard R J Nucl Med; 2016 May; 57(5):721-7. PubMed ID: 26697964 [TBL] [Abstract][Full Text] [Related]
40. Accuracy and Precision of Partial-Volume Correction in Oncological PET/CT Studies. Cysouw MCF; Kramer GM; Hoekstra OS; Frings V; de Langen AJ; Smit EF; van den Eertwegh AJ; Oprea-Lager DE; Boellaard R J Nucl Med; 2016 Oct; 57(10):1642-1649. PubMed ID: 27230933 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]